Accuray Incorporated has declared the installation of a CyberKnife VSI system at the Leon-Berard Cancer Multidisciplinary Center (CLB) in Lyon, France, thereby recognizing this cancer centre to be the first in Europe to include this latest product of the CyberKnife category.
The Leon- Berard Cancer Center is committed to the treatment of cancer, with its R&D unit in Rhone-Alpes. The Department of Radiation Oncology is already well supplied with one devoted scanner, five therapy accelerators and one suite for internal radiotherapy. The incorporation of the CyberKnife VSI robot into the Radiation Department will further enhance the options of cancer treatment for the medical center’s 2,000 yearly patients.
Christian Carrie, M.D., Head of the Radiation Oncology Department at CLB stated that this new product of Accuray Incorporated will enable them to provide more characteristic radiation treatment for high risk cancer patients. He further added that even though CyberKnife can provide only traditional mode of fractionation, its unique features of high precision and competence in the therapy of mobile targets like liver and prostate made them to select this robotic system.
With the addition of the CyberKnife VSI system, the Medical center can provide treatment for those cancer indications outside the cranium. This new innovation will also broaden the series of treatments offered in the Cancer Center including intensity modulated conformal radiotherapy (IMRT), respiratory gating radiation therapy, interstitial brachytherapy, extracranial stereotactic radiation therapy and total body irradiation (TBI).
Guillaume Tetard, Senior Director of Sales, Accuray EIMEA (Europe India Middle East and Africa) expressed his happiness over working with CLB and stated that availing modern technologies in cancer treatment has become critical with greater increase in cancer identification in France. He also expressed his company’s determination in enhancing cancer therapy all over Europe by providing more treatment options for both clinicians and patients.
The CyberKnife VSI System features instantaneous tracking and rectification abilities to provide high-dose radiation with maximum accuracy to destroy cancer cells, including those tumors that are highly capricious due to the body’s physiological functions. Cyberknife system offers locally confined therapy for both cancerous and non-cancerous abrasions. This product does not depend on sub-optimal methods like gating that explains the mobility. Stabilizing head and body frames which are highly uneasy for the patients are also not employed. The target tracing methodologies of the CyberKnife VSI System is of high standard which can deliver an accurate amount of radiation, thereby providing a trouble-free experience for the cancer patients. Each treatment session lasts between 20 to45 minutes and the entire treatment is concluded within one to five sessions. It was reported that in most situations, patients can return to their normal life instantly following the treatment.